T cells and myeloid cells have a central role in the immunopathology of multiple sclerosis, but it is unclear how B cell depletion therapy efficiently controls the inflammatory response in relapsing-remitting multiple sclerosis (RRMS). Now, Li et al. show that the frequency of B cells expressing granulocyte–macrophage colony-stimulating factor (GM-CSF) is increased in patients with RRMS and that these B cells activate myeloid cells. Furthermore, B cell-depletion therapy reduced the pro-inflammatory responses of myeloid cells, and this anti-inflammatory effect persisted as new B cells reconstituted.
The authors compared the cytokine profiles of B cells from healthy donors with those from patients with RRMS. In healthy humans, a population of pro-inflammatory effector memory B cells expressing GM-CSF, high levels of interleukin-6 (IL-6) and tumour necrosis factor was identified. The frequency of these GM-CSF+ B cells was increased in blood samples from patients with RRMS, and B cell receptor activation further augmented the difference in the frequency of GM-CSF+ B cells between the two study groups.
RRMS-derived GM-CSF+ B cells produced more GM-CSF
Next, the authors examined the effect of GM-CSF+ B cells on myeloid cells. Supernatants from cultures enriched in GM-CSF+ B cells enhanced human macrophage secretion of pro-inflammatory cytokines, such as IL-1β, IL-6 and IL-12, and decreased secretion of the anti-inflammatory cytokine IL-10. Of note, this effect was abolished when GM-CSF was blocked in B cell supernatants. The production of GM-CSF was regulated by signal transducer and activator of transcription 5 (STAT5) and STAT6, as phosphorylation of these proteins induced B cell expression of GM-CSF and decreased induction of IL-10. Interestingly, RRMS-derived GM-CSF+ B cells produced more GM-CSF and induced higher pro-inflammatory cytokine responses in macrophages of both healthy controls and patients with RRMS compared with GM-CSF+ B cells from healthy controls. Thus, GM-CSF from B cells can promote inflammation, and this effect is enhanced in RRMS-derived GM-CSF+ B cells.
Finally, the authors compared the responses of monocyte-derived macrophages from samples collected before and after patients with RRMS underwent B cell-depletion therapy with a CD20-specific antibody. Macrophages obtained just after B cell depletion showed reduced secretion of IL-6 and IL-12, and increased secretion of IL-10, compared with pre-treatment macrophages from the same patient. Moreover, these less inflammatory macrophages persisted after B cell reconstitution, in keeping with lower frequencies and reduced responses of GM-CSF+ B cells within the reconstituted B cell population.
Taken together, the results indicate that modifying the profile of B cells can modulate myeloid cell responses, including reduced pro-inflammatory myeloid cell responses in patients with multiple sclerosis who are treated with B cell depletion therapy.
References
Li, R. et al. Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy. Sci. Transl Med. 7, 310ra166 (2015)
Related links
Related links
Related links in Nature Research
Rights and permissions
About this article
Cite this article
Kugelberg, E. Resetting the scene. Nat Rev Immunol 15, 727 (2015). https://doi.org/10.1038/nri3937
Published:
Issue Date:
DOI: https://doi.org/10.1038/nri3937